Barclays Maintains Intellia Therapeutics (NTLA) Overweight Recommendation

Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia shares jump on positive gene-editing data

Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis ...

Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? | The Motley Fool

Intellia Therapeutics Doses First Patient in Landm | Newswise

5 Top Stock Gainers for Monday: Intellia Therapeutics, QAD, Etsy, Nvidia

Why Intellia Therapeutics Stock Is Surging Tuesday - Intellia Therapeutics (NASDAQ:NTLA)

Biotech Plummets 73% After Side Effects 'Shock' Its Lead Drug